Show simple item record

dc.contributor.authorCruzat, Andrea
dc.contributor.authorWitkin, Deborah
dc.contributor.authorBaniasadi, Neda
dc.contributor.authorZheng, Lixin
dc.contributor.authorCiolino, Joseph B
dc.contributor.authorJurkunas, Ula V.
dc.contributor.authorChodosh, James
dc.contributor.authorPavan-Langston, Deborah
dc.contributor.authorDana, Reza
dc.contributor.authorHamrah, Pedram
dc.date.accessioned2018-02-23T20:23:37Z
dc.date.issued2011
dc.identifierQuick submit: 2017-06-18T20:45:48-0400
dc.identifier.citationCruzat, Andrea, Deborah Witkin, Neda Baniasadi, Lixin Zheng, Joseph B. Ciolino, Ula V. Jurkunas, James Chodosh, Deborah Pavan-Langston, Reza Dana, and Pedram Hamrah. 2011. “Inflammation and the Nervous System: The Connection in the Cornea in Patients with Infectious Keratitis.” Investigative Opthalmology & Visual Science 52 (8) (July 11): 5136. doi:10.1167/iovs.10-7048.en_US
dc.identifier.issn1552-5783en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34864855
dc.description.abstractPurpose.: To investigate the ability of bevacizumab to penetrate the cornea after topical application or subconjunctival injection. Methods.: Bevacizumab 1% was topically applied three times a day to the corneas of mice (BALB/c) with intact corneas (n = 14), and with corneal neovascularization (n = 14). Animals were euthanized at 1, 6, 12, and 24 hours, and 2, 4, and 7 days for immunohistochemical analyses. Donkey anti-human IgG labeled with Cy3 was used for bevacizumab immunoreactivity detection. Additionally, one-time topical bevacizumab 1% was tested in corneas with denuded epithelium (n = 16). In another group (n = 16), a single dose of 0.5 mg bevacizumab was injected subconjunctivally. Animals were euthanized at 1, 6, and 24 hours, and 2, 4, 7, 14, and 21 days for immunohistochemical studies. Results.: Bevacizumab was barely detected beyond the very superficial layer of the corneal epithelium in mice with intact corneas even after 7 days of topical administration. Application of bevacizumab in mice with corneal neovascularization; however, showed variable penetration into the corneal stroma. Experimentation with single application of topical bevacizumab in corneas with denuded epithelium or subconjunctivally injected bevacizumab showed intense staining for bevacizumab. Conclusions.: Topically applied bevacizumab has limited capacity to penetrate the corneas with intact epithelium. However, bevacizumab can penetrate the neovascularized cornea after topical application. This study demonstrates that subconjunctivally injected bevacizumab in eyes with an intact cornea penetrates well into the corneal stroma.en_US
dc.language.isoen_USen_US
dc.publisherAssociation for Research in Vision and Ophthalmology (ARVO)en_US
dc.relation.isversionofdoi:10.1167/iovs.10-7048en_US
dash.licenseLAA
dc.titleInflammation and the Nervous System: The Connection in the Cornea in Patients with Infectious Keratitisen_US
dc.typeJournal Articleen_US
dc.date.updated2017-06-19T00:45:49Z
dc.description.versionVersion of Recorden_US
dc.relation.journalInvestigative Opthalmology & Visual Scienceen_US
dash.depositing.authorDana, Reza
dc.date.available2011
dc.date.available2018-02-23T20:23:37Z
dc.identifier.doi10.1167/iovs.10-7048*
dash.contributor.affiliatedCiolino, Joseph
dash.contributor.affiliatedChodosh, James
dash.contributor.affiliatedJurkunas, Ula
dash.contributor.affiliatedCruzat, Andrea
dash.contributor.affiliatedBaniasadi, Neda
dash.contributor.affiliatedDana, Reza


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record